Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment

Mild Cognitive Impairment Clinical Trial

Official title:

The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02982642
• Other study ID #: Z20055424
• Status: Withdrawn
• Phase: Phase 4
• Start date: January 2017
• Est. completion date: December 2018

Study information

• Verified date: March 2021
• Source: Dongzhimen Hospital, Beijing
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a 52-weeks, multicenter, randomized, double-blind, placebo controlled, parallel trial which will be carried out in 15 centers around China. The study population includes amnestic mild cognitive impairment patients (planned a total of 240) aged 55-85 in both gender. Participants will be randomly allocated to 1612 capsules (1.14g per time, 3 times per day) or placebo for a 52-weeks double-blind treatment period. The primary outcome measure is change from baseline in the Alzheimer's Disease Assessment Scale- Cognition Subscale (ADAS-cog) and rate of conversion to dementia. The secondary outcomes are changes from baseline in the Mini-Mental State Examination (MMSE), Delayed Story Recall test (DSR), Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24). Safety is being assessed by observing side effects and adverse reaction during the entire treatment period. Statistical analysis will be conducted according to per-protocol population and intend-to-treat population and the safety will be analyzed in safety set.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

Patients should be enrolled if they met the following criteria[14]:

1. cognitive complaints from the patients or their families;

2. objective evidence for memory impairment, delayed story recall test(DSR)<12.6(age50-64 less than15.5,65-74less than 12.5,older 75 less than10);

3. normal general cognitive function, with Mini-Mental State Examination (MMSE) score of between 24 and 30 (including 30);

4. preservation of activities of daily living, with Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24) score between 38 and 52;

5. cognitive disorders as evidenced by clinical evaluation, with clinical dementia rating scale=0.5,memory domain = 0.5;

6. absence of dementia, not sufficiently impaired cognitively and functionally to meet DSM-IV criteria,

7. enough vision and hearing to accomplishment neuropsychological test;

8. capability to read words and write simple sentence;

9. capability and willingness to give informed consent and to comply with the study procedures.

Exclusion Criteria:

The patients would be ineligible if they had the following conditions:

1. non amnestic Mild cognitive impairment;

2. meeting the diagnostic criteria for dementia;

3. cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, epilepsy vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor ,or drug abuse or alcohol abuse

4. having significant psychiatric disease, depression, the Hamilton depression scale >12; CT or MRI scan showed central nervous system infections Infarction or focal lesions within 12 months,the Hachinski Ischemic Scale (HIS)>4;

5. combined following disease: diabetes; poor controlled hypertension or severe arrhythmias; or suffered from heart infarction within 3 months; severe asthma or COPD; severe indigestion; gastrointestinal tract obstruction; gastroduodenal ulcer;

6. used cholinesterase inhibitors or memantine within 1 month;

7. history of hypersensitivity to the treatment drugs;

8. concomitant drugs with the potential to interfere with cognition;

9. administration of other investigational drugs; severe impairment of the functions of the kidney or liver;

10. vegetarians or contraindications for animal innards.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Drug:
• 1612 capsule
Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
• Placebos
Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day

Locations

Country	Name	City	State
China	Dongzhimen Hospital ,Beijing University of Chinese Medicine	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Dongzhimen Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in cognitive scores: Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)	Cognition will accessed with the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), at baseline (day 1 clinic visit) and week 4, week 12, week 24 ,week 36 , week 48 and week 52.	52 weeks
Primary	Change from baseline to end of double-blind treatment of rate of dementia conversion from mild cognitive impairment	The rate of demention conversion will accessed from baselin at week 0 and week 4, week 12, week 24 ,week 36 , week 48 and week 52.	52 weeks
Secondary	Change from baseline to end of double-blind treatment of Mini-Mental State Examination(MMSE)	Cognition will accessed with the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), at baseline (day 1 clinic visit) and week 4, week 12, week 24 ,week 36 , week 48 and week 52.	52 weeks
Secondary	Change from baseline to end of double-blind treatment of Delayed Story Recall test (DSR)	Memory will accessed with the delayed story recall test(DSR), at baseline (day 1 clinic visit) and week 4, week 12, week 24 ,week 36 , week 48 and week 52.	52 weeks
Secondary	Change from baseline to end of double-blind treatment of Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24)	Ability of daily living will accessed with the Alzheimer's Disease Cooperative Study/Activities of Daily Living scale adapted for MCI patients (ADCS/MCI/ADL24), at baseline (day 1 clinic visit) and week 4, week 12, week 24 ,week 36 , week 48 and week 52.	52 weeks